The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1

Journal of Cellular Biochemistry

Volumn 101, Issue 1, 2007, Pages 259-270

  Schmid, Gerald ^a   Guba, Markus ^a   Ischenko, Ivan ^a   Papyan, Armine ^a   Joka, Mareile ^a   Schrepfer, Sabine ^a   Bruns, Christiane J ^a   Jauch, Karl Walter ^a   Heeschen, Christopher ^a   Graeb, Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Angiogenesis; CXCR4; FTY720; Immunosuppression; SEW2871; Sphingosine 1 phosphate; Tumor growth

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FINGOLIMOD; MATRIGEL; NEUTRALIZING ANTIBODY; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; C57BL 6 MOUSE; CANCER INHIBITION; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEWIS CARCINOMA; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TRANSACTIVATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; CELL DIVISION; CELLS, CULTURED; COCULTURE TECHNIQUES; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMININ; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUTRALIZATION TESTS; OXADIAZOLES; PROPYLENE GLYCOLS; PROTEOGLYCANS; RECEPTORS, CXCR4; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; THIOPHENES; TRANS-ACTIVATION (GENETICS); TRANSPLANTATION, ISOGENEIC; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 34147095398     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21181     Document Type: Article

References (46)

1. Armulik A, Abramsson A, Betsholtz C. 2005. Endothelial/pericyte interactions. Circ Res 97:512-523.
2. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. 2003. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278:47408-47415.
3. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KRœ. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457.
4. Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature 438:932-936.
5. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC. 2005. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 117:1039-1048.
6. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. 1998. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 351:623-628.
7. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, Kremers WK, Stegall MD. 2004. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77:1555-1561.
8. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y, Okumoto T. 1994. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 47:208-215.
9. Gallo P, Agozzino L, Angelini A, Arbustini E, Bartoloni G, Bernucci P, Bonacina E, Bosman C, Catani G, di Gioia C, Giordana C, Leone O, Motta T, Pucci A, Rocco M. 1997. Causes of late failure after heart transplantation: A ten-year survey. J Heart Lung Transplant 16:1113-1121.
10. Gerhardt H, Betsholtz C. 2003. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314:15-23.
11. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. 2002. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135.
12. Guba M, Graeb C, Jauch KW, Geissler EK. 2004. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77:1777-1782.
13. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, Yamori T, Tsuruo T, Kawabe T, Miyagishi M, Taira K, Sata M, Omata M. 2005. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65:5864-5871.
14. Hla T, Maciag T. 1990. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 265:9308-9313.
15. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. 2005. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 4:1430-1438.
16. Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. 2000. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 70:1335-1342.
17. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
18. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. 2004. Cancer after kidney transplantation in the United States. Am J Transplant 4:905-913.
19. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. 2005. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883-889.
20. Kimura T, Boehmler AM, Seitz G, Kuci S, Wiesner T, Brinkmann V, Kanz L, Mohle R. 2004. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood 103:4478-4486.
21. Korff T, Augustin HG. 1998. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143:1341-1352.
22. Korff T, Kimmina S, Martiny-Baron G, Augustin HG. 2001. Blood vessel maturation in a 3-dimensional spheroidal coculture model: Direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 15:447-457.
23. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N, Imamura M. 2000. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 6:3530-3535.
24. Kragh M, Hjarnaa PJ, Bramm E, Kristjansen PE, Rygaard J, Binderup L. 2003. In vivo chamber angiogenesis assay: An optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. Int J Oncol 22:305-311.
25. Kwon YG, Min JK, Kim KM, Lee DJ, Billiar TR, Kim YM. 2001. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J Biol Chem 276:10627-10633.
26. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J. 2006. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221-231.
27. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T. 1999. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99:301-312.
28. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST. 2004a. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 25:2397-2405.
29. Lee WJ, Yoo HS, Suh PG, Oh S, Lim JS, Lee YM. 2004b. Sphingosine mediates FTY720-induced apoptosis in LLC-PK1 cells. Exp Mol Med 36:420-427.
30. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. 2000. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106:951-961.
31. Lynch KR. 2002. Lysophospholipid receptor nomenclature. Biochim Biophys Acta 1582:70-71.
32. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349.
33. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360.
34. Murdoch C, Monk PN, Finn A. 1999. Cxc chemokine receptor expression on human endothelial cells. Cytokine 11:704-712.
35. Paik JH, Chae S, Lee MJ, Thangada S, Hla T. 2001. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3-and beta1-containing integrins. J Biol Chem 276:11830-11837.
36. Saba JD, Hla T. 2004. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 94:724-734.
37. Sanchez T, Hla T. 2004. Structural and functional characteristics of S1P receptors. J Cell Biochem 92:913-922.
38. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T. 2003. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278:47281-47290.
39. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. 2004. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839-13848.
40. Schmid G, Guba M, Papyan A, Ischenko I, Bruckel M, Bruns CJ, Jauch KW, Graeb C. 2005. FTY720 inhibits tumor growth and angiogenesis. Transplant Proc 37:110-111.
41. Sheil AG, Disney AP, Mathew TH, Amiss N. 1993. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25:1383-1384.
42. Spiegel S, Milstien S. 2003. Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397-407.
43. Tanaka T, Takahara S, Hatori M, Suzuki K, Wang J, Ichimaru N, Suzuki S, Morozumi K, Okuyama A, Yamanaka H. 2002. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett 181:165-171.
44. Valente JF, Hricik D, Weigel K, Seaman D, Knauss T, Siegel CT, Bodziak K, Schulak JA. 2003. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 3:1128-1134.
45. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. 2002. Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? Transplantation 74:1746-1751.
46. Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, Billich A. 2006. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454-1458.